We are thrilled to provide a significant update on our novel SARM1 intra-molecular glue inhibitor program. https://lnkd.in/g9r7KdXn
关于我们
At Asha Therapeutics, we are leveraging our expertise in computational chemistry and neurobiology to develop novel therapeutics that enable the re-engineering and restoration of neurological function. Our lead assets demonstrate efficacy in both human cells and murine models of neurodegenerative diseases including Parkinson’s Disease, Stroke, Alzheimer’s Disease, ALS, and Multiple System Atrophy.
- 网站
-
https://www.ashatherapeutics.com/
Asha Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
Asha Therapeutics员工
-
Brian Knight
Director of Medicinal Chemistry at Asha Therapeutics
-
Bradlee Heckmann, Ph.D.
Co-founder, President & Chief Scientific Officer, Asha Therapeutics | Member, USF Health Neuroscience Institute
-
Julia Hallisey
Asha Therapeutics, COO and Director of Investor Relations
-
Gopal Thinakaran
CEO Byrd Alzheimer's Center and Research Institute / Associate Dean for Neuroscience Research
动态
-
Asha Therapeutics is excited to be presenting at #ALS Nexus hosted by @alsassociation / @thealsassociation. Our CSO, Dr. Bradlee Heckmann (@bradleeheckmann) will be sharing data on our lead SARM1 inhibitor ASHA-624 in ALS and providing perspectives on neuronal repair and regeneration opportunities as a panelist. Learn more by visiting?alsnexus.org and ashatherapeutics.com!